Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday. The drug, known scientifically as ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...